NCT00093353 2026-04-14
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
New Approaches to Neuroblastoma Therapy Consortium
Azienda Sanitaria Locale di Asti
Eli Lilly and Company
Adcytherix SAS
Dana-Farber Cancer Institute
Massachusetts General Hospital